Publications by authors named "Kalaiselvi Dharuman"
Efficacy and tolerability of a 4-month ofloxacin-containing regimen compared to a 6-month regimen in the treatment of patients with superficial lymph node tuberculosis: a randomized trial.
BMC Infect Dis
July 2024
Article Synopsis
- Tuberculosis lymphadenitis is a common form of extra-pulmonary TB, traditionally requiring six months of treatment, but this study explored a potential four-month regimen using ofloxacin.
- The trial involved adult TB patients randomly assigned to either a four-month ofloxacin-based treatment or a traditional six-month regimen, with outcomes assessed based on TB recurrence and treatment success.
- Results showed the four-month regimen was as effective and safe as the six-month control, with similar rates of favorable response and manageable side effects, making it a promising alternative.
4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India - a randomised clinical trial.
Trop Med Int Health
April 2020
Background: Shortening tuberculosis (TB) treatment duration is a research priority. We tested the efficacy and safety of 3- and 4-month regimens containing moxifloxacin in a randomised clinical trial in pulmonary TB (PTB) patients in South India.
Methods: New, sputum-positive, adult, HIV-negative, non-diabetic PTB patients were randomised to 3- or 4-month moxifloxacin regimens [moxifloxacin (M), isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E)] or to a control regimen (2H R Z E /4R H ) [C].
Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.
Clin Infect Dis
November 2014
Background: Rapid sputum culture conversion at 2 months indicates the sterilizing capacity and potential of regimens to shorten duration of tuberculosis treatment. We compared results of sputum culture conversion by moxifloxacin and control regimens and identified factors affecting sputum culture positivity after 2 months of treatment.
Methods: Human immunodeficiency virus-uninfected adults with newly diagnosed smear-positive pulmonary tuberculosis were randomized to receive a 3- or 4-month moxifloxacin regimen (moxifloxacin [M], isoniazid [H], rifampicin [R], pyrazinamide [Z], ethambutol [E]) or the control regimen (RHZE thrice weekly).